Rolandic Mitochondrial Encephalomyelopathy and MT-ND3 Mutations
Received 27 August 2008; accepted 16 February 2009.
Mitochondrial encephalopathies may be caused by mutations in the respiratory chain complex I subunit genes. Described here are the cases of two pediatric patients who presented with MELAS-like calcarine lesions in addition to novel, bilateral rolandic lesions and epilepsia partialis continua, secondary to MT-ND3 mutations. Data were collected included neurologic symptoms, serial brain imaging, metabolic evaluations, skeletal muscle biopsies, mitochondrial biochemical and molecular testing. Permission for publication was given by the families. Muscle histology revealed nonspecific changes, with no ragged red or blue or COX-negative fibers. Sequencing of the mitochondrial DNA indicated patient 2 to be homoplasmic in muscle for the mt.10158T>C mutation in the ND3 subunit and Patient 1 to be 75% heteroplasmic for the mt.10191T>C mutation, also in ND3. Bilateral rolandic lesions and epilepsia partialis continua accompanied by suspicion of mitochondrial disease are indications to search for an underlying mutation in the MT-ND3 gene.
∗Division of Neurology and Pediatric Emergency Medicine, Hospital for Sick Children, Toronto, Ontario, Canada
†Division of Clinical and Metabolic Genetics, Hospital for Sick Children, Toronto, Ontario, Canada
§Division of Rheumatology and Pediatric Emergency Medicine, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada
∗∗Department of Diagnostic Imaging, Division of Neuroradiology, Hospital for Sick Children, Toronto, Ontario, Canada
¶Metabolism Research Program, Research Institute, Department of Biochemistry, Hospital for Sick Children, Toronto, Ontario, Canada
‡Division of Neurology, Alberta Children's Hospital, Calgary, Alberta, Canada
#Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
††Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
Communications should be addressed to: Dr. Feigenbaum; Division of Clinical and Metabolic Genetics; The Hospital for Sick Children; 555 University Avenue; Toronto, Ontario M5G 1X8, Canada.